Verrica Pharmaceuticals
VRCA
67 hedge funds and large institutions have $58.5M invested in Verrica Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 17 increasing their positions, 19 reducing their positions, and 8 closing their positions.
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
6% more funds holding
Funds holding: 63 → 67 (+4)
0.1% more ownership
Funds ownership: 3.48% → 3.58% (+0.1%)
11% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 19
31% less capital invested
Capital invested by funds: $84.2M → $58.5M (-$25.8M)
88% less call options, than puts
Call options by funds: $16K | Put options by funds: $133K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.74M |
| 2 |
CP
Caligan Partners
New York
|
+$1.32M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$848K |
| 4 |
Morgan Stanley
New York
|
+$362K |
| 5 |
BlackRock
New York
|
+$242K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.18M |
| 2 |
Renaissance Technologies
New York
|
-$463K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$360K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$311K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$197K |
VRCA Hedge Fund Activity: Q3 2023 in Review
67 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q3 2023, worth a combined $58.5M — down 31% from $84.2M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new VRCA positions and 8 closed out — a net gain of 4 holders — while 17 added to existing stakes and 19 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $1.74M. The largest seller was Millennium Management, cutting an estimated $1.18M.
- 67 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q3 2023, up from 63 in Q2 2023.
- Funds reported $58.5M of Verrica Pharmaceuticals stock for Q3 2023, down 31% quarter-over-quarter.
- 12 funds opened new Verrica Pharmaceuticals positions in Q3 2023 and 8 closed out, a net change of +4 holders.
- The largest Verrica Pharmaceuticals buyer in Q3 2023 was Fidelity Investments, an estimated $1.74M added.
- The largest Verrica Pharmaceuticals seller in Q3 2023 was Millennium Management, an estimated $1.18M sold.
Based on aggregated 13F filings for Q3 2023.